Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Total Current Liabilities (2016 - 2026)

Protara Therapeutics' Total Current Liabilities history spans 14 years, with the latest figure at $8.9 million for Q1 2026.

  • Quarterly Total Current Liabilities rose 27.13% to $8.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $8.9 million through Mar 2026, up 27.13% year-over-year, with the annual reading at $10.9 million for FY2025, 0.2% changed from the prior year.
  • Total Current Liabilities came in at $8.9 million for Q1 2026, down from $10.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $11.0 million in Q4 2024 to a low of $2.9 million in Q1 2022.
  • The 5-year median for Total Current Liabilities is $6.4 million (2023), against an average of $6.9 million.
  • Year-over-year, Total Current Liabilities surged 124.05% in 2023 and then fell 14.18% in 2024.
  • Protara Therapeutics' Total Current Liabilities stood at $5.7 million in 2022, then grew by 7.13% to $6.1 million in 2023, then skyrocketed by 78.26% to $11.0 million in 2024, then dropped by 0.2% to $10.9 million in 2025, then decreased by 18.44% to $8.9 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Total Current Liabilities are $8.9 million (Q1 2026), $10.9 million (Q4 2025), and $9.9 million (Q3 2025).